We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Engineered COVID-19 Antibody Enables Extremely Rapid Identification of SARS-CoV-2 in Nasal Mucus, Saliva, and Blood

By LabMedica International staff writers
Posted on 20 Oct 2020
An engineered monoclonal antibody against the COVID-19 virus spike protein could enable extremely rapid identification of the SARS-CoV-2 virus in nasal mucus, saliva, and blood, as well as potentially allow for rapid identification of the virus present on surfaces, such as food, cell phones, door handles, etc., through testing only a small sample.

The new class of anti-spike protein monoclonal antibodies against COVID-19 was created by researchers at Halberd Corporation (Jackson Center, PA, USA) and Arizona State University (ASU Tempe, AZ, USA). More...
Halberd has begun the process of filing the first of multiple planned joint patent applications for this new class of antibody and will not publicly disclose details concerning the rapid identification methodology until appropriate patent protections are in place. Halberd scientists believe that the breakthrough could help solve the COVID-19 pandemic by accelerating identification of the SARS-CoV-2 virus, and the scientific analysis of the effectiveness of COVID-19 therapeutics.

Scientists from Halberd believe that rapid identification is essential to permit effectively initiating therapeutics in the earliest phases of COVID-19. Early identification and treatment could substantially curtail the spread of COVID-19.

“The progress over the past month has been phenomenal and is already yielding patentable intellectual property. We foresee this as just the first of many potential patent applications to address the rapid detection, prevention, and treatment of COVID-19,” said Dr. Patricio Reyes, Chief Technical Officer of Halberd Corporation.

Related Links:
Arizona State University
Halberd Corporation



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.